Laboratorio Reig Jofre, S.A. (BME:RJF)
Spain · Delayed Price · Currency is EUR 2.700
-0.010 (-0.37%)
May 18, 2026, 3:29 PM CET
Laboratorio Reig Jofre Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 335.01 | 336.68 | 341.37 | 317.95 | 274.21 | 239.87 | |
Revenue Growth (YoY) | -2.30% | -1.37% | 7.36% | 15.95% | 14.32% | 2.61% |
Cost of Revenue | 138.03 | 143.48 | 147.92 | 141.06 | 119.12 | 96.9 |
Gross Profit | 196.98 | 193.2 | 193.45 | 176.89 | 155.09 | 142.97 |
Selling, General & Admin | 111.1 | 108.86 | 100.78 | 89.79 | 81.87 | 73.9 |
Other Operating Expenses | 55.34 | 53.86 | 54.58 | 51.96 | 42.79 | 41.75 |
Operating Expenses | 191.57 | 187.51 | 178.71 | 164.9 | 145.72 | 133.7 |
Operating Income | 5.4 | 5.7 | 14.73 | 11.99 | 9.37 | 9.28 |
Interest Expense | -1.91 | -1.36 | -1 | -0.75 | -0.69 | -0.68 |
Interest & Investment Income | 5.03 | 5.03 | 0.29 | 0.06 | 0.1 | 0.05 |
Earnings From Equity Investments | -0.86 | -0.31 | -0.12 | 0.98 | 1.59 | 0.09 |
Currency Exchange Gain (Loss) | 0.26 | 0.26 | 0.01 | 0.07 | 0.06 | -0.36 |
Other Non Operating Income (Expenses) | -0.99 | -1.2 | 0.29 | -0.15 | -0.7 | -2.15 |
EBT Excluding Unusual Items | 6.93 | 8.12 | 14.2 | 12.21 | 9.74 | 6.23 |
Impairment of Goodwill | -0.63 | -0.63 | -1 | - | -0.4 | - |
Gain (Loss) on Sale of Assets | -1.17 | -1.17 | -1.38 | -0.72 | -0.57 | -0.44 |
Asset Writedown | -0.49 | - | - | -1 | - | 0 |
Pretax Income | 4.64 | 6.32 | 11.82 | 10.5 | 8.76 | 5.79 |
Income Tax Expense | 0.25 | 1.32 | 1.36 | 1.1 | 0.66 | 0.71 |
Earnings From Continuing Operations | 4.39 | 5 | 10.47 | 9.4 | 8.11 | 5.08 |
Minority Interest in Earnings | 0.02 | 0.02 | -0.09 | 0.01 | 0 | 0.01 |
Net Income | 4.42 | 5.02 | 10.38 | 9.41 | 8.11 | 5.09 |
Net Income to Common | 4.42 | 5.02 | 10.38 | 9.41 | 8.11 | 5.09 |
Net Income Growth | -59.05% | -51.64% | 10.37% | 16.04% | 59.21% | -10.23% |
Shares Outstanding (Basic) | 81 | 81 | 81 | 80 | 79 | 78 |
Shares Outstanding (Diluted) | 81 | 81 | 81 | 80 | 79 | 78 |
Shares Change (YoY) | - | 0.01% | 1.65% | 1.50% | 1.32% | 1.13% |
EPS (Basic) | 0.05 | 0.06 | 0.13 | 0.12 | 0.10 | 0.07 |
EPS (Diluted) | 0.05 | 0.06 | 0.13 | 0.12 | 0.10 | 0.07 |
EPS Growth | - | -52.97% | 8.58% | 17.49% | 52.89% | -6.56% |
Free Cash Flow | - | -13.78 | 11.08 | 6.65 | 5.2 | -4.73 |
Free Cash Flow Per Share | - | -0.17 | 0.14 | 0.08 | 0.07 | -0.06 |
Dividend Per Share | - | - | 0.049 | 0.040 | 0.040 | 0.040 |
Dividend Growth | - | - | 22.50% | - | - | -11.11% |
Gross Margin | 58.80% | 57.38% | 56.67% | 55.63% | 56.56% | 59.60% |
Operating Margin | 1.61% | 1.69% | 4.32% | 3.77% | 3.42% | 3.87% |
Profit Margin | 1.32% | 1.49% | 3.04% | 2.96% | 2.96% | 2.12% |
Free Cash Flow Margin | - | -4.09% | 3.25% | 2.09% | 1.90% | -1.97% |
EBITDA | 22.74 | 22.84 | 31.1 | 28.3 | 22.56 | 20.36 |
EBITDA Margin | 6.79% | 6.78% | 9.11% | 8.90% | 8.23% | 8.49% |
D&A For EBITDA | 17.33 | 17.14 | 16.37 | 16.31 | 13.19 | 11.08 |
EBIT | 5.4 | 5.7 | 14.73 | 11.99 | 9.37 | 9.28 |
EBIT Margin | 1.61% | 1.69% | 4.32% | 3.77% | 3.42% | 3.87% |
Effective Tax Rate | 5.41% | 20.92% | 11.46% | 10.47% | 7.51% | 12.31% |
Advertising Expenses | - | 12.42 | 11.96 | 12.96 | 10.99 | 9 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.